Multimodality approach in non-metastatic tumors
What will happen?
•
Neoadjuvant trials with immunotherapy planned
Major pathologic response in 7/18 (39%) patients treated with
2 doses of nivolumab
(Forde ESMO 16)
•
Ongoing studies with consolidation immunotherapy in stage III
(PACIFIC, NCT 02343952 trials)
•
Ongoing studies of integration of CT/RT/immunotherapy (Nicolas-
ETOP)
•
We expect immunotherapy to be integrated into stage III
management without eliminating CT
